The FINANCIAL — A study published in The Journal of Clinical Psychiatry shows that long-acting INVEGA SUSTENNA (paliperidone palmitate) was effective six months longer than commonly prescribed oral ...

The word "blockbuster" gets thrown around quite a bit when it comes to prescription drugs. But now, the blockbuster status of Invega Sustenna, an injectible antipsychotic drug used to treat ...

The US Food and Drug Administration (FDA) has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera, Janssen Pharmaceuticals) for the ...

The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering. Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are ...

DUBLIN, April 9, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a ...

The word "blockbuster" gets thrown around quite a bit when it comes to prescription drugs. But now, the blockbuster status of Invega Sustenna, an injectible antipsychotic drug used to treat ...

Johnson & Johnson has had little trouble keeping sales from its Invega portfolio of long-acting antipsychotic injectables in the billions. Now, it's angling for approval of an even more durable ...

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...

Invega Hafyera (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia. It’s given as an injection into your muscle by your doctor or another healthcare professional. Invega ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

(RTTNews) - Janssen Pharmaceutical, Inc., wholly-owned by Johnson & Johnson (JNJ), announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...

John M. Kane, MD: So back to that question about why they are so underutilized. I guess we’ve raised some of the issues. Some of it is maybe the hassle that clinicians might feel. There’s perhaps some ...